Stage III ovarian epithelial cancer is a serious condition where cancer cells have spread beyond the ovaries into the abdominal area, but treatment options exist to help manage the disease and improve quality of life.

How Treatment for Advanced Ovarian Cancer Works

When ovarian epithelial cancer reaches stage III, it means the disease has moved beyond the pelvis into the lining of the abdomen or nearby lymph nodes. At this point, the main goals of treatment are to remove as much cancer as possible, prevent further spread, and help patients maintain the best possible quality of life. Treatment decisions depend on many factors, including where exactly the cancer has spread, whether a specialized surgeon believes all visible cancer can be removed, and the patient’s overall health and strength.^[1]

Stage III ovarian cancer is divided into smaller groups based on how far the cancer has traveled. Stage 3A means cancer has reached the lymph nodes at the back of the abdomen or tiny amounts of cancer cells are present in the abdominal lining. Stage 3B indicates visible cancer growths in the abdomen that are 2 centimeters or smaller. Stage 3C means the cancer growths in the abdomen are larger than 2 centimeters, or cancer appears on the surface of organs like the spleen or liver.^[1]

It is important to understand that while stage III cancer is advanced, many people with this diagnosis respond well to treatment. The combination of surgery and medication has helped numerous patients live longer and better lives. Medical societies and cancer organizations continuously update their guidelines based on the latest research to ensure patients receive the most effective care available.^[1]

Standard Treatment Options for Stage III Ovarian Cancer

Surgery as the Foundation of Treatment

For most people with stage III ovarian epithelial cancer, surgery is the first step in treatment. A specialist surgeon called a gynaecological oncologist performs an operation to remove both ovaries, both fallopian tubes, and the uterus including the cervix. During the same surgery, the surgeon examines the pelvis and abdomen carefully to see where cancer has spread and whether it has reached the lymph nodes.^[1]

The main goal of this surgery is to remove as much cancer as possible. This approach is called cytoreductive surgery or debulking surgery. The surgeon tries to take out all visible tumors, which sometimes means removing portions of other organs where cancer has spread, such as parts of the intestines, liver, or bladder. Removing as much cancer as possible improves the chances that follow-up treatments will work better.^[1]

In some cases, surgery might not be the first treatment. If the cancer has spread very widely or if the patient is not strong enough for a major operation, doctors may recommend starting with chemotherapy first. This is called neoadjuvant chemotherapy. The chemotherapy shrinks the tumors, making them easier to remove later during interval cytoreductive surgery.^[1]

Chemotherapy After Surgery

After surgery, most patients receive chemotherapy to destroy any remaining cancer cells that are too small to see or remove during the operation. This is known as adjuvant chemotherapy. The standard approach uses a combination of two types of drugs: a platinum-based drug and a taxane drug.^[1]

The most commonly used combination is carboplatin and paclitaxel. Carboplatin belongs to the platinum family of drugs, which work by damaging the DNA inside cancer cells so they cannot grow and divide. Paclitaxel is a taxane drug that interferes with the structures cancer cells need to divide. These drugs are given directly into a vein, and treatment usually involves several cycles spread over several months.^[16]

Some patients may receive chemotherapy in a different way. In a procedure called hyperthermic intraperitoneal chemotherapy or HIPEC, heated chemotherapy is delivered directly into the abdomen during surgery. The heat helps the chemotherapy work more effectively, and placing it directly into the abdomen targets cancer cells in that area more precisely. However, this approach is not suitable for everyone and requires careful discussion with the treatment team.^[1]

Targeted Cancer Drugs

Some patients may benefit from targeted cancer drugs, which work differently than traditional chemotherapy. These medications focus on specific features of cancer cells rather than attacking all rapidly dividing cells. One example is bevacizumab, also known by the brand name Avastin. This drug blocks a protein called vascular endothelial growth factor or VEGF, which cancer cells use to create new blood vessels for their growth.^[3]

Bevacizumab may be given together with chemotherapy at first, and then continued on its own for up to a year. It is not suitable for all patients, and doctors decide whether to recommend it based on the individual’s specific situation and the characteristics of their cancer.^[3]

Side Effects of Standard Treatment

All cancer treatments can cause side effects, though not everyone experiences them in the same way. Surgery can lead to pain, fatigue, and a long recovery period. If parts of the intestines or other organs are removed, patients may need to adjust to changes in digestion or other bodily functions.

Chemotherapy often causes side effects because it affects healthy cells along with cancer cells. Common problems include nausea and vomiting, hair loss, fatigue, increased risk of infections due to low white blood cell counts, and numbness or tingling in the hands and feet. Many of these side effects can be managed with supportive medications and care, and they typically improve after treatment ends.^[6]

Targeted drugs like bevacizumab have their own set of possible side effects. These can include high blood pressure, protein in the urine, and in rare cases, bleeding or problems with wound healing. Doctors monitor patients closely during treatment to catch and manage these issues early.^[13]

When Surgery Is Not Possible

If surgery cannot be performed because the cancer has spread too extensively or the patient’s health makes surgery too risky, chemotherapy can still be offered on its own. The goal in this situation is to shrink the cancer as much as possible and slow its growth, helping to control symptoms and improve quality of life. Patients may also receive treatments to relieve specific symptoms, such as draining fluid that builds up in the abdomen (called ascites) or addressing a blocked bowel. In some cases, radiation therapy is used to relieve pain or other symptoms.^[1]

Treatment Being Tested in Clinical Trials

Researchers around the world are constantly working to develop better treatments for stage III ovarian cancer. Clinical trials test new drugs, new combinations of existing drugs, and entirely new approaches to fighting cancer. Participating in a clinical trial gives patients access to cutting-edge therapies that are not yet widely available, while also contributing to scientific knowledge that will help future patients.^[1]

Understanding Clinical Trial Phases

Clinical trials happen in stages, each with a specific purpose. Phase I trials test a new treatment in a small group of people to evaluate its safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more participants and focus on whether the treatment works against the cancer, while continuing to monitor safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to see which works better and has fewer side effects. Understanding these phases helps patients know what to expect if they consider joining a trial.

Innovative Molecules and Biological Agents

One promising area of research involves drugs that target the molecular pathways cancer cells use to grow and spread. Scientists have discovered that ovarian cancer cells often rely on specific signals and proteins to survive. By blocking these signals, new drugs can slow or stop cancer growth without harming normal cells as much as traditional chemotherapy does.

Bevacizumab, mentioned earlier as an approved targeted drug, is also being studied in various combinations and schedules in clinical trials. Researchers are testing whether giving it at different times or with different chemotherapy drugs can improve results for patients with recurrent or resistant ovarian cancer. Early results suggest that combining bevacizumab with standard chemotherapy can lead to longer periods without cancer progression in some patients, though more research is needed to confirm these benefits.^[13]

Immunotherapy Approaches

Another exciting area of research is immunotherapy, which helps the body’s own immune system recognize and attack cancer cells. Some clinical trials are testing drugs called checkpoint inhibitors, which release the brakes on immune cells, allowing them to fight cancer more effectively. While immunotherapy has shown great success in some types of cancer, researchers are still working to understand which ovarian cancer patients will benefit most from these treatments.

Clinical trials are also exploring combinations of immunotherapy drugs with chemotherapy or targeted drugs. The idea is that using multiple approaches together might be more effective than any single treatment alone. Some trials have reported promising early results, with patients experiencing tumor shrinkage and improved disease control, but these treatments are still considered experimental.

Gene Therapy and Personalized Medicine

Advances in understanding the genetic changes that drive ovarian cancer have opened new doors for treatment. Some patients have cancers with specific genetic mutations that make them vulnerable to certain drugs. For example, patients with mutations in genes called BRCA1 or BRCA2 may respond well to drugs called PARP inhibitors, which exploit weaknesses in how these cancer cells repair their DNA.

Clinical trials are testing PARP inhibitors in various settings for stage III ovarian cancer. Some trials give these drugs as maintenance therapy after chemotherapy to help prevent the cancer from coming back. Others test them in combination with other treatments. Results from several studies have shown that PARP inhibitors can extend the time before cancer returns in patients with certain genetic features.^[12]

Location and Eligibility for Clinical Trials

Clinical trials for ovarian cancer are conducted in many countries, including the United States, various European nations, and increasingly in other parts of the world. Each trial has specific requirements about who can participate, based on factors such as the stage and type of cancer, previous treatments received, and overall health status. Patients interested in clinical trials should discuss options with their oncologist, who can help identify suitable studies and explain the potential benefits and risks.

Promising Trial Results

Some clinical trials have already reported encouraging outcomes. For instance, certain trials combining targeted drugs with chemotherapy showed improvements in how long patients lived without their cancer getting worse. Others demonstrated that new drug combinations could shrink tumors in patients whose cancer had not responded to standard treatments. While these results are preliminary and the treatments remain experimental, they offer hope that more effective options will become available in the future.

Most common treatment methods

• Surgery (Cytoreductive/Debulking)
  • Removal of both ovaries, fallopian tubes, uterus, and cervix by a specialized gynecological oncologist
  • Removal of as much visible cancer as possible from the pelvis and abdomen
  • May include removal of portions of other affected organs such as intestines, liver, or bladder
  • Can be performed after initial chemotherapy (interval cytoreductive surgery) if cancer is too extensive for immediate surgery
• Chemotherapy
  • Combination of carboplatin (platinum drug) and paclitaxel (taxane drug) given intravenously
  • Administered after surgery (adjuvant chemotherapy) to destroy remaining cancer cells
  • May be given before surgery (neoadjuvant chemotherapy) to shrink tumors
  • Treatment typically involves multiple cycles over several months
  • Hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated chemotherapy directly into the abdomen during surgery
• Targeted Cancer Drugs
  • Bevacizumab (Avastin) blocks VEGF protein to prevent cancer from creating new blood vessels
  • Can be given with chemotherapy initially, then continued alone for up to a year
  • PARP inhibitors for patients with specific genetic mutations (BRCA1/BRCA2)
  • May be used as maintenance therapy after chemotherapy to prevent recurrence
• Supportive and Palliative Care
  • Treatment for fluid accumulation in the abdomen (ascites)
  • Management of bowel obstruction
  • Radiation therapy to relieve pain or other symptoms
  • Pain management and symptom control when curative treatment is not possible